业绩总结 - 2024年第一季度总收入为6.49亿美元，同比增长9%[10] - VOXZOGO产品收入为1.53亿美元，同比增长74%[10] - VOXZOGO治疗的儿童数量同比增长102%[10] - 非GAAP稀释每股收益增长速度是总收入的两倍[10] - 预计2024年全年总收入指引不变，非GAAP运营利润率和非GAAP稀释每股收益指引提高[10] - 非GAAP运营利润率为23.8%至25%[10] - 非GAAP稀释每股收益为2.75至2.95美元[10] - 2024年第一季度GAAP每股收益为0.46美元，非GAAP每股收益为0.71美元[20] - 2024年第一季度GAAP加权平均摊薄股数为199.3万股，非GAAP加权平均摊薄股数为199.3万股[21]

财务表现 - BioMarin Pharmaceutical (BMRN) 2024年第一季度营收为6.4883亿美元，同比增长8.8%[1] - EPS为0.71美元，较去年同期的0.60美元有所增长[1] - 公司营收略低于分析师预期，但EPS超出预期[1] 公司表现 - BioMarin在最新季度的关键指标表现良好，包括产品净收入、特许权和其他收入等[4][5][6][7][8][9][10][11][12][13] 股票表现 - BioMarin股票过去一个月回报率为+4.9%，表现优于Zacks S&P 500综合指数的-3%变化[14]

BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $0.71 per share, beating the Zacks Consensus Estimate of $0.60 per share. This compares to earnings of $0.60 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 18.33%. A quarter ago, it was expected that this rare disease biopharmaceutical would post earnings of $0.44 per share when it actually produced earnings of $0.49, delivering a surprise of 11.36%.Over the l ...

总收入及产品收入 - 2024年第一季度总收入为6.49亿美元，同比增长9%[1] - VOXZOGO®净产品收入为1.53亿美元，同比增长74%[1] - 2024年第一季度，BioMarin Pharmaceutical Inc.的净产品收入为6,378.15万美元，较2023年同期的5,864.26万美元增长[28] 全球治疗儿童数量 - 全球使用VOXZOGO治疗的儿童数量从上一季度增加了500多人，截至季末总数超过3100人[3] 财务指导和运营 - 2024年全年指导方针中，总收入得到确认，非GAAP运营利润率和非GAAP每股收益提高[1] - 2024年全年财务指导中，BioMarin提高了非GAAP运营利润率和非GAAP稀释每股收益的指导[17] - BioMarin不提供关于GAAP报告财务指标的指导，但更新了2024年全年的非GAAP稀释每股收益指导[22] 财务表现 - 2024年第一季度，GAAP净收入同比增加3,780万美元，达到8,870万美元[5] - 2024年第一季度，非GAAP收入同比增加2,390万美元，达到1.397亿美元[6] - BioMarin Pharmaceutical Inc.的研发支出为2,049.87万美元，较2023年同期的1,718.46万美元增长[28] - BioMarin Pharmaceutical Inc.的净利润为8,866.2万美元，较2023年同期的5,085.2万美元增长[28] 营业收入和利润 - 非GAAP调整后的营业收入同比增长13%达到75.1亿美元[35] - 非GAAP调整后的营业利润同比增长10.2%至65.9亿美元[35] 每股收益 - 非GAAP调整后的每股收益同比增长18.3%至0.71美元[35] 可转换债务 - 公司在2024年的可转换债务下发行的普通股未计入GAAP稀释股份，如果转换，公司将在2023年发行440万股[36]

Investors are always looking for stocks that are poised to beat at earnings season and BioMarin Pharmaceutical Inc. (BMRN) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.That is because BioMarin is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pre ...

Analysts on Wall Street project that BioMarin Pharmaceutical (BMRN) will announce quarterly earnings of $0.60 per share in its forthcoming report, representing no change year over year. Revenues are projected to reach $649.75 million, increasing 8.9% from the same quarter last year.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.Before a company announ ...

公司介绍 - BioMarin Pharmaceutical Inc.成立于1997年，是一家全球生物技术公司，致力于通过基因发现改善生活，开发和商业化针对基因疾病根本原因的靶向疗法[3] - BioMarin的研发能力已经为罕见遗传疾病患者开发了八种变革性的商业疗法，公司独特的药物发现方法已经产生了一个多样化的商业、临床和临床前候选药物管线[3] 财务业绩电话会议 - BioMarin Pharmaceutical Inc.宣布首席执行官将主持电话会议和网络直播，讨论2024年第一季度财务业绩和一般业务更新[1] - 可以通过BioMarin网站的投资者部分访问电话会议的现场音频网络直播，电话会议的重播将在网站上存档一周[2]

Although many popular biotech stocks peaked in 2020 and early 2021 and then started to decline, early 2024 has seen signs of recovery and a return of investors’ trust. Nonetheless, this biotech stock powered through the period, achieving miracle growth and maintaining its decades-long tradition of positive returns.The biotech stock in today’s limelight is BioMarin Pharmaceutical (NASDAQ: BMRN), a biotechnology and pharmaceutical company focusing on tackling rare genetic diseases through an innovative portfo ...

Ms. Hubbard Brings More than 20 Years of Experience in the Biopharmaceutical and Diagnostics Industries Appointment Effective May 20, 2024 SAN RAFAEL, Calif., March 7, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that Cristin Hubbard has been named executive vice president and chief commercial officer. Ms. Hubbard will assume responsibility for the company's global commercial operations, effective May 20, succeeding Jeff Ajer. Ms. Hubbard is a proven leader who brings to ...

公司活动 - BioMarin Pharmaceutical Inc.宣布将参加四场投资者会议[1] - 公司的首席财务官Brian Mueller将在多个会议上进行演讲和举办一对一会议[2] 公司背景 - BioMarin成立于1997年，致力于通过基因发现改善生活[3]